Deutsche Bank Ag\ Humanigen, Inc Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.76 - $3.33 $78,605 - $148,724	-44,662 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.81 - $3.97 $15,629 - $34,280	8,635 Added 23.97%	44,662 $135,000
Q4 2021 Feb 11, 2022	BUY	$3.66 - $8.22 $21,231 - $47,684	5,801 Added 19.19%	36,027 $134,000
Q3 2021 Nov 04, 2021	SELL	$5.93 - $17.83 $2,982 - $8,968	-503 Reduced 1.64%	30,226 $179,000
Q2 2021 Aug 11, 2021	BUY	$13.54 - $22.74 $416,070 - $698,777	30,729 New	30,729 $534,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.